Considerations in assessing the immunotoxic potential of investigational drugs

被引:0
|
作者
Hastings K.L. [1 ]
Ahn C.-H. [1 ]
Alam S.N. [1 ]
Aszalos A. [1 ]
Choi Y.S. [1 ]
Jessop J.J. [1 ]
Weaver J.L. [1 ]
机构
[1] Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland
来源
Drug information journal : DIJ / Drug Information Association | 1997年 / 31卷 / 4期
关键词
Allergenicity; Immunotoxicity; Pharmaceuticals;
D O I
10.1177/009286159703100438
中图分类号
学科分类号
摘要
Determination of the potential for an investigational drug to adversely affect the immune system is a standard component of nonclinical toxicology studies. Potential adverse immune effects include drug-induced hypersensitivity, immunosuppression, autoimmunity, immunostimulation, and drug antigenicity. Although immunotoxicology studies are rarely incorporated under a single heading in submissions, sponsors frequently conduct specialized assays to determine immunotoxic effects. Skin and respiratory sensitization studies are usually conducted if a drug is to be administered topically or by the inhalation route, respectively. These studies are designed to model clinical effects rather than to determine sensitization potential based on underlying immune mechanisms. Passive and active anaphylaxis assays are used to demonstrate biological effects indicative of drug antigenicity. Studies designed to determine immunosuppressive or immunostimulatory potential are often conducted when these effects are related to pharmacodynamic properties of the drug. Nonclinical studies designed to detect potential to induce autoimmune reactions are rarely conducted, primarily due to a lack of adequately characterized assays. In addition, newer assays designed to determine sensitization and autoimmunity-inducing potential are being evaluated. © 1997, Drug Information Association. All rights reserved.
引用
收藏
页码:1357 / 1361
页数:4
相关论文
共 50 条
  • [31] Investigational drugs for visceral leishmaniasis
    Sundar, Shyam
    Chakravarty, Jaya
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (01) : 43 - 59
  • [32] Investigational drugs for the treatment of osteoarthritis
    Wang, Kang
    Xu, Jianhua
    Hunter, David J.
    Ding, Changhai
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (12) : 1539 - 1556
  • [33] Investigational drugs for neuroendocrine tumours
    Granberg, Dan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (05) : 601 - 608
  • [34] ADMINISTRATION OF PARENTERAL INVESTIGATIONAL DRUGS
    不详
    JOURNAL OF INFUSION NURSING, 2006, 29 : S78 - S78
  • [35] Perspectives on investigational drugs for acromegaly
    Stoermann, Sylvere
    Schopohl, Jochen
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 381 - 384
  • [36] Investigational drugs for eating disorders
    Crow, S
    Brown, E
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (03) : 491 - 499
  • [37] Investigational drugs for hepatitis C
    Flisiak, Robert
    Parfieniuk, Anna
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (01) : 63 - 75
  • [38] THERAPY WITH INVESTIGATIONAL ANTIARRHYTHMIC DRUGS
    MEAD, RH
    HARRISON, DC
    MEDICAL CLINICS OF NORTH AMERICA, 1984, 68 (05) : 1321 - 1337
  • [39] Investigational drugs in systemic vasculitis
    Mirouse, Adrien
    Cacoub, Patrice
    Desbois, Anne Claire
    Comarmond, Cloe
    Pagnoux, Christian
    Saadoun, David
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1049 - 1061
  • [40] Expanded access to investigational drugs
    Douglas, Natalie
    Genetic Engineering and Biotechnology News, 2010, 30 (02):